ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,277.51
0.80%
Dow Jones
38,686.32
1.51%
US Dollar vs MXN
16.99024
-0.30%
Brent Oil
81.295
0.00%
Bitcoin
67,732.03
0.37%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Ionis Pharmaceuticals Inc (IONS)

  7. Ionis Pharmaceuticals Inc (IONS) Noticias

IONS Ionis Pharmaceuticals Inc

37.57
1.02 (2.79%)
31 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Ionis Pharmaceuticals Inc IONS NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
1.02 2.79% 37.57 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
36.55 35.95 38.07 37.57 36.55
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
31/5/202406:15EDGAR2Form 8-K - Current report
31/5/202406:00PRNUSIonis presents positive results from OASIS-HAE and OASISplus..
28/5/202406:00PRNUSIonis to hold donidalorsen Phase 3 data webcast
23/5/202406:00PRNUSNew data from the Phase 3 NEURO-TTRansform study evaluating..
16/5/202406:30GLOBEBiogen and Ionis Announce Topline Phase 1/2 Study Results of..
16/5/202406:30PRNUSIonis and Biogen Announce Topline Phase 1/2 Study Results of..
16/5/202406:00PRNUSIonis announces positive topline results from Phase 1/2a..
15/5/202406:05PRNUSIonis to host 2024 virtual Annual Meeting of Stockholders
13/5/202416:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/5/202415:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/5/202414:55EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202410:15EDGAR2Form 8-K - Current report
07/5/202406:00PRNUSIonis reports first quarter 2024 financial results
25/4/202406:00PRNUSIonis Publishes 2023 Corporate Responsibility Report
23/4/202406:05PRNUSIonis to hold first quarter 2024 financial results webcast
07/4/202408:48PRNUSIonis presents positive results from Phase 3 Balance study..
01/4/202406:05PRNUSIonis to present at upcoming investor conferences
28/3/202406:05PRNUSIonis to hold olezarsen Phase 3 data webcast
25/3/202407:18PRNUSPositive olezarsen Phase 3 data in familial chylomicronemia..
13/3/202406:00PRNUSIonis announces positive results from Phase 2 study of..
06/3/202406:30GLOBENew Biomarker Data Add Further Evidence Supporting the..
04/3/202418:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202418:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202418:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202418:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202418:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202408:10EDGAR2Form 8-K - Current report
29/2/202408:05PRNUSIonis announces new chief global product strategy officer to..
28/2/202406:05PRNUSIonis to present at upcoming investor conferences
21/2/202410:17EDGAR2Form 8-K - Current report
21/2/202406:00PRNUSIonis reports fourth quarter and full year 2023 financial..
20/2/202409:39EDGAR2Form 144/A - Report of proposed sale of securities: [Amend]
16/2/202418:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202415:34EDGAR2Form 144 - Report of proposed sale of securities
15/2/202406:00PRNUSOlezarsen receives Orphan Drug designation from U.S. FDA for..
14/2/202409:04EDGAR2Form SC 13G - Statement of acquisition of beneficial..
13/2/202405:09EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/2/202406:00PRNUSEplontersen granted U.S. FDA Fast Track designation for..
07/2/202406:05PRNUSIonis to hold fourth quarter and full year 2023 financial..
02/2/202418:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202418:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202418:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202418:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202418:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202418:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202418:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202418:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202416:34EDGAR2Form 144 - Report of proposed sale of securities
02/2/202416:31EDGAR2Form 144 - Report of proposed sale of securities
02/2/202416:30EDGAR2Form 144 - Report of proposed sale of securities

Su Consulta Reciente

NASDAQ
IONS
Ionis Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados